Featured Research

from universities, journals, and other organizations

Molecular subtyping of breast cancer can better identify women at high risk of disease recurrence

Date:
March 6, 2014
Source:
University of South Florida
Summary:
A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study reports.

Dr. Cox clarified that discordance does not necessarily show that some genomic test results were wrong.
Credit: Image courtesy of University of South Florida

A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study led by the University of South Florida reports. This sophisticated genetic profiling of an individual's specific tumor offers an additional resource to help identify patients who would most benefit from chemotherapy and those who would not.

The findings by researchers from USF and other institutions were presented in a scientific poster at the Miami Breast Cancer Conference, held March 6-9 in Miami Beach, Fla.

"The most important takeaway for our colleagues in breast cancer diagnosis and treatment is the potential value of molecular subtyping to personalize and improve each woman's treatment," said principal investigator Charles E. Cox, MD, McCann Foundation Endowed Professor of Breast Surgery, USF Health Morsani College of Medicine.

Molecular subtyping is a way of classifying breast cancer tumors into one of four genetically-distinct categories, or subtypes: Luminal A, Luminal B, Basal (a subset of triple negative), and HER2-type. Each subtype responds differently to different kinds of treatments, and some subtypes indicate a higher risk of disease recurrence.

"Our data showed that a substantial number of breast cancer patients -- classified as low risk by one particular genomic test -- turn out to be at high risk of recurrence once we determined their subtype," Dr. Cox said. "These are mostly Luminal B patients, and their physicians might not fully understand their patient's situation unless they do subtyping."

The USF study examined why different genomic tests for breast cancer sometimes provide contradictory information about risk of recurrence. The key findings involved the 70-gene MammaPrint® test; the 21-gene Oncotype DX® test, which is an earlier commercially available test; and Mammostrat®, a gene profiling test performed on slides of the breast tumor by a pathologist. The tests have generally been assumed to provide equivalent information about recurrence risk, but that is proving not to be the case.

Researchers examined tumor samples from a total of 148 patients. The greatest discordance (lack of agreement) about risk of disease recurrence occurred in a group of 51 patients. Of those 51, all were stratified by MammaPrint as high risk of recurrence, while Oncotype classified 18 of them (35 percent) as low risk.

BluePrint®, an 80-gene test to identify a tumor's molecular subtype, was also used for those stratified by MammaPrint. This process revealed that the 51 patients were Luminal B, a molecular subtype with a high risk of recurrence.

Patients with a high risk of recurrence are normally counseled to receive chemotherapy following surgery to prevent the cancer from returning. In contrast, women whose subtype has a low risk of recurrence (Luminal A) will not benefit from the addition of chemotherapy. They may thus be able to safely avoid chemotherapy and its potentially damaging side effects. At the same time, they can be prescribed treatments such as hormonal therapy known to benefit those with their subtype.

The additional information provided by genomic tests and molecular subtyping may help reduce overall treatment costs for breast cancer, by targeting chemotherapy only for those women who will benefit from it, Dr. Cox said "Personalized treatment guided by these tests may also extend the time that patients are free of their cancer."

Registered nurse George Ann Vincent, a Tampa, Fla. resident and a patient of Dr. Cox, was diagnosed with early-stage breast cancer last year. The 70-gene test determined that her tumor had a high risk of recurrence, so she was prescribed chemotherapy.

"I'm certainly grateful that I'm getting the treatments that are right for me," Vincent said. "Chemotherapy is no picnic, but it can save lives. The genomic tests I took made me confident I was being sent in absolutely the right direction."

Dr. Cox clarified that discordance does not necessarily show that some genomic test results were wrong.

"These tests use different genes and were validated on different types of populations," he said. "But if physicians use molecular subtyping as we did in this study, they will have valuable, additional information to guide the appropriate treatment for each patient."

Using molecular subtyping in combination with traditional biomarkers, like tumor grade and hormone receptor status, for determining the biological nature of a woman's cancer is a recommended guideline for breast cancer treatment in both the United States and Europe, Dr. Cox said.


Story Source:

The above story is based on materials provided by University of South Florida. Note: Materials may be edited for content and length.


Cite This Page:

University of South Florida. "Molecular subtyping of breast cancer can better identify women at high risk of disease recurrence." ScienceDaily. ScienceDaily, 6 March 2014. <www.sciencedaily.com/releases/2014/03/140306211042.htm>.
University of South Florida. (2014, March 6). Molecular subtyping of breast cancer can better identify women at high risk of disease recurrence. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2014/03/140306211042.htm
University of South Florida. "Molecular subtyping of breast cancer can better identify women at high risk of disease recurrence." ScienceDaily. www.sciencedaily.com/releases/2014/03/140306211042.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins